Nadine J Ortner Selected Research

Isradipine (Dynacirc)

1/2021	Voltage-Gated Ca2+ Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease?
1/2020	Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder.
12/2017	Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nadine J Ortner Research Topics

Disease

2	Parkinson Disease (Parkinson's Disease) 01/2021 - 12/2017
2	Hypertension (High Blood Pressure) 01/2016 - 01/2015
2	Ischemia 01/2016 - 01/2015
1	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2022
1	Movement Disorders (Movement Disorder) 01/2021
1	Disease Progression 01/2021
1	Neurodevelopmental Disorders 01/2020
1	Adenoma (Adenomas) 01/2020
1	Autistic Disorder (Autism) 01/2020

Drug/Important Bio-Agent (IBA)

3	Isradipine (Dynacirc)FDA LinkGeneric 01/2021 - 12/2017
2	1,4-dihydropyridine (dihydropyridine)IBA 01/2021 - 01/2020
2	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 12/2017
1	DisulfidesIBA 01/2022
1	AldosteroneIBA 01/2020
1	Calcium Channels (Calcium Channel)IBA 01/2016
1	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 01/2015
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2015

Therapy/Procedure

1	Therapeutics 01/2021